Versatility of autologous growth factor concentrate therapy in early-stage androgenetic alopecia: A case report

Androgenetic alopecia (AGA) is a common progressive condition in men, influenced by genetic predisposition and androgen sensitivity. Conventional therapies such as minoxidil and finasteride provide limited efficacy and require long-term use, often associated with side effects. Regenerative approaches like autologous growth factor concentrate (GFC) have emerged as promising alternatives. This report presents a 28-year-old male with Norwood–Hamilton Grade III vertex AGA, treated with standardized GFC injections administered monthly for four sessions. Post-treatment, the patient demonstrated reduced hair shedding, improved density (72 to 98 hairs/ cm 2 ), and an 18% increase in shaft thickness, with no adverse effects. Patient satisfaction was rated 9/10. These findings suggest that GFC is a safe, effective, and minimally invasive modality for early AGA management.